antithrombotic treatment in patients with coronary artery ectasia | ||||
| Minia Journal of Medical Research | ||||
| Articles in Press, Accepted Manuscript, Available Online from 07 October 2024 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjmr.2024.312577.1787 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Amr Mostafa Setohi Abdelhafez1; Ahmad Khaled Mohamed  2; Mohamed Esmail Khalil Esmail 3; Nasser Mohammed Taha4; Hany Taha Taha5
| ||||
| 1cardiology department ,faculty of medicine ,minia university | ||||
| 2Cardiology department, Faculty of medicine, Minya University | ||||
| 3Department of Ophthalmology, Faculty of Medicine, Minia University, Minia, Egypt | ||||
| 4cardiology department,Minia university, Egypt | ||||
| 5Cardiology department, Faculty of medicine, Minia university | ||||
| Abstract | ||||
| Coronary artery ectasia (CAE) is a type of atherosclerotic coronary artery diseasea which is detected in 3%–8% of individuals undergoing coronary angiography, either by itself or in conjunction with stenotic lesions. Regardless of the degree of stenotic lesions, the existence of ectatic segments can exacerbate exercise-induced angina and myocardial infarction by contributing to slow blood flow. Antiplatelet medications are the cornerstone of treatment for isolated CAE, where prognosis is improved. Aim: This study aims to evaluate the rivaroxaban effect on endothelial function in individuals with coronary artery ectasia whether slow flow is evident or not in addition to patients with slow flow along with normal coronary artery. Methods: patients were grouped into three groups which are patients with CAE with slow flow, patients with CAE without slow flow and patients with slow flow with normal coronary arteries. We compared endothelial function measured by flow mediated dilation (FMD) method before and after one month of treatment by rivaroxaban 2.5 mg twice daily Results: FMD was significantly improved after treatment by rivaroxaban in all treated patients groups Conclusion: Rivaroxaban 2.5 mg twice daily improves endothelial function in patients with CAE and/or slow flow | ||||
| Keywords | ||||
| Coronary artery ectasia; slow flow; rivaroxaban | ||||
|
Statistics Article View: 187 |
||||
